User login
The U.S. Food and Drug Administration (FDA) has now approved three generic arsenic trioxide products for use in patients with acute promyelocytic leukemia (APL).
Two of the products—from Zydus Cadila and Amring Pharmaceuticals—were approved on November 13.
The third—from Fresenius Kabi—was approved in August and launched in the United States last month.
All three injectable arsenic trioxide products (1 mg/mL) are generic versions of Teva’s Trisenox.
Since 2000, Trisenox has been FDA-approved to induce remission and as consolidation therapy for patients with APL who are refractory to, or have relapsed after, retinoid and anthracycline chemotherapy, and whose APL is characterized by presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
In January, the FDA approved Trisenox for use in combination with tretinoin to treat adults with newly diagnosed, low-risk APL with the t(15;17) translocation or PML/RAR-alpha gene expression.
The U.S. Food and Drug Administration (FDA) has now approved three generic arsenic trioxide products for use in patients with acute promyelocytic leukemia (APL).
Two of the products—from Zydus Cadila and Amring Pharmaceuticals—were approved on November 13.
The third—from Fresenius Kabi—was approved in August and launched in the United States last month.
All three injectable arsenic trioxide products (1 mg/mL) are generic versions of Teva’s Trisenox.
Since 2000, Trisenox has been FDA-approved to induce remission and as consolidation therapy for patients with APL who are refractory to, or have relapsed after, retinoid and anthracycline chemotherapy, and whose APL is characterized by presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
In January, the FDA approved Trisenox for use in combination with tretinoin to treat adults with newly diagnosed, low-risk APL with the t(15;17) translocation or PML/RAR-alpha gene expression.
The U.S. Food and Drug Administration (FDA) has now approved three generic arsenic trioxide products for use in patients with acute promyelocytic leukemia (APL).
Two of the products—from Zydus Cadila and Amring Pharmaceuticals—were approved on November 13.
The third—from Fresenius Kabi—was approved in August and launched in the United States last month.
All three injectable arsenic trioxide products (1 mg/mL) are generic versions of Teva’s Trisenox.
Since 2000, Trisenox has been FDA-approved to induce remission and as consolidation therapy for patients with APL who are refractory to, or have relapsed after, retinoid and anthracycline chemotherapy, and whose APL is characterized by presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
In January, the FDA approved Trisenox for use in combination with tretinoin to treat adults with newly diagnosed, low-risk APL with the t(15;17) translocation or PML/RAR-alpha gene expression.